TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion
TriLink BioTechnologies (TriLink ® ), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers. TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials.
TriLink has reliably delivered GMP services to its customers since the debut of its first cGMP manufacturing facility in 2015. Built to meet the need of a rapidly growing market, the new cGMP facility is expected to contribute to the development of vital mRNA therapeutics. The building has been designed for the cGMP manufacture of mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.
“The expansion of our cGMP mRNA manufacturing capabilities marks a major milestone for TriLink and our partners,” said Becky Buzzeo, Chief Commercial Officer at Maravai LifeSciences. “Drug developers will soon be able to leverage our team’s 25-plus years of industry expertise, helping to take critical therapeutics from concept to plasmid DNA through to late-phase clinical mRNA drug substance manufacturing with ease.”
Just minutes from the company’s San Diego headquarters, the new facility boasts ISO 7 cleanrooms and increased mRNA capacity (1g to >50g per batch), with comprehensive in-house analytical services also available. “Our team took great care in building and designing our new facility– it’s truly been a labor of love,” added Rob Carpenter, Vice President of Engineering at TriLink. “In addition to having access to a state-of-the-art facility, developers will also have a direct line to our experienced team to help with process optimization, scale-up, validation, and qualification capabilities.”
To learn more about TriLink’s products and services, visit trilinkbiotech.com
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is helping to realize the power and potential of mRNA. As a global leader in nucleic acid and mRNA solutions for more than 25 years, TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its proprietary CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information about TriLink, visit www.trilinkbiotech.com.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the expectation that our expanded manufacturing capabilities will simplify and contribute to mRNA therapeutics development, our ability to attract and serve late-phase drug developers, an increase of mRNA-based therapeutics and vaccines entering later-stage clinical trials, and our ability to help to take critical therapeutics from concept through late-phase clinical mRNA drug substance manufacturing constitute forward-looking statements identified by words like “expect,” “estimate,” “may,” “soon,” “nears,” “slated,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation and uncertainties related to construction and permitting delays, availability and delays in delivery of equipment, continued validation of the safety and effectiveness of our technology, and new scientific developments and competition from other products. These and other risks and uncertainties are described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K, as well as other reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005159/en/
Contact information
Liz Robinson, PR Account Supervisor at CG Life, lrobinson@cglife.com, 847-702-8099
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health20.1.2026 15:00:00 EET | Press release
Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization's work on oral health. The four-year funding commitment will help expand oral health education, support integration of oral health into national health systems, and raise awareness of oral health as a public health priority. This initiative builds on Colgate’s commitment to providing communities with oral health education and resources. The Company recently announced that the Colgate Bright Smiles, Bright Futures® program has reached approximately two billion children and their families around the world since 1991 with oral health education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120050760/en/ “At Colgate-Palmolive, we are driven by our purpose to reimagine a healthier future for all – and to make more smiles. We’re launching this collaboration with the WHO Foundation given its unique
FGS Global Launches AI Advisory Practice and Acquires Threat Intelligence Firm Memetica20.1.2026 15:00:00 EET | Press release
FGS Global, the world's leading stakeholder strategy firm, today announced the launch of its AI Advisory practice and the acquisition of Memetica, a specialist technology consultancy in AI-driven threat detection and mitigation across social, dark web and fringe platforms. The new practice sits within FGS Global's recently formed AI and Innovation group led by Aaron Kwittken, Global Head of AI and Innovation. The AI Advisory practice builds on and consolidates FGS Global's deliberate, years-long investment in AI capabilities to support surging client demand for strategic and practical guidance on leveraging AI and emerging technologies to enhance communications efficacy, reputational defense and operational efficiencies. This critical work is supported by a global team of more than 200 strategists, analysts, engineers, developers, designers and data scientists across AI strategy, digital influence, campaigns, earned, paid and owned media, influencer engagement, special situations and c
CAS IP Finder Expands Intellectual Property Search Access Across Organizations20.1.2026 15:00:00 EET | Press release
CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces complete functionality for CAS IP Finder™, powered by STN™. CAS STNext® customers can now access the full intellectual property search solution across all search methods, expanded content collections, and advanced analysis tools. Patent volume continues to grow, and scientific disciplines are increasingly interconnected, making intellectual property research more complex and increasing the risk of missed prior art. Organizations traditionally chose between empowering specialized searchers with comprehensive tools or providing limited capabilities to broader teams. CAS IP Finder eliminates that compromise by providing flexible access points that connect users of all experience levels to curated content and precise search tools. "As scientific and patent data grow in complexity, organizations need IP search solutions that enable access across entire teams," said Manuel Guzman, Pres
Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas20.1.2026 15:00:00 EET | Press release
Parse Biosciences and Graph Therapeutics (Graph) today announced a strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration will leverage Graph's lab-in-the-loop platform with Parse's GigaLab to profile hundreds of millions of cells from patients with immune diseases under systematic perturbation, making the immune system’s highly dynamic behavior accessible to AI-first drug discovery and development. This endeavor derisks and speeds up the development of new curative therapies for patients with immune-mediated diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120419953/en/ Autoimmune and immune-mediated diseases are driven by context- and patient-specific immune cell population responses, making it difficult for drug developers to identify drug targets and predict clinical outcomes. The partnership between Graph and Parse addresses this challenge
SEPHORA and OLIVE YOUNG Partner to Bring the Best of Korean Beauty to SEPHORA Consumers20.1.2026 15:00:00 EET | Press release
SEPHORA, the global leader in prestige beauty retail, and CJ OLIVE YOUNG, Korea's leading beauty and health retailer, announced today a new strategic partnership to bring the best curation of cutting-edge and sought-after Korean beauty to SEPHORA consumers around the world. The partnership will debut this fall as a visionary omnichannel partnership in the United States, Canada, Hong Kong SAR and Southeast Asia (Singapore, Malaysia, Thailand), with expansion into additional regions including the Middle East, the UK and Australia in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120395650/en/ The partnership will provide SEPHORA customers with a dedicated zone curated by OLIVE YOUNG online and in stores, allowing them to discover a unique assortment of the most popular Korean beauty brands, and the newest trend-driven Korean health and beauty products, all carefully curated by OLIVE YOUNG. The partnership also combine
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom